{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:12:42Z","timestamp":1781716362596,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10549-023-06892-5","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:02:27Z","timestamp":1678168947000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil"],"prefix":"10.1007","volume":"199","author":[{"given":"Patricia","family":"Mazzonetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Milanezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla M.","family":"Monfredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"dos Santos Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darine","family":"Villela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edenir Inez","family":"Palmero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thereza L.","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Migliavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristovam","family":"Scapulatempo-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-0430","authenticated-orcid":false,"given":"Ilana","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"6892_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665\u2013676","journal-title":"Nat Rev Cancer"},{"key":"6892_CR2","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","volume":"11","author":"SR Lakhani","year":"2005","unstructured":"Lakhani SR et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175\u20135180","journal-title":"Clin Cancer Res"},{"key":"6892_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4:814\u2013819","journal-title":"Nat Rev Cancer"},{"key":"6892_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171\u2013182","journal-title":"Cell"},{"key":"6892_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3343\/alm.2020.40.2.114","volume":"40","author":"A Lee","year":"2020","unstructured":"Lee A, Moon BI, Kim TH (2020) BRCA1\/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med 40:114\u2013121","journal-title":"Ann Lab Med"},{"issue":"302","key":"6892_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"1979","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 1979(302):643\u2013646","journal-title":"Science"},{"key":"6892_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA\u2014J Am Med Assoc 317:2402\u20132416","journal-title":"JAMA\u2014J Am Med Assoc"},{"key":"6892_CR8","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.00531","volume":"39","author":"NJ Boddicker","year":"2021","unstructured":"Boddicker NJ et al (2021) Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol 39:3430\u20133440","journal-title":"J Clin Oncol"},{"key":"6892_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","volume":"144","author":"K Anderson","year":"2006","unstructured":"Anderson K et al (2006) Annals of internal medicine article or a BRCA2 mutation. Ann Intern Med 144:397\u2013406","journal-title":"Ann Intern Med"},{"key":"6892_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6874-10-28","volume":"10","author":"M Salhab","year":"2010","unstructured":"Salhab M, Bismohun S, Mokbel K (2010) Risk-reducing strategies for women carrying brca1\/2 mutations with a focus on prophylactic surgery. BMC Womens Health 10:1\u201310","journal-title":"BMC Womens Health"},{"key":"6892_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/OP.21.00382","volume":"18","author":"YL Liu","year":"2022","unstructured":"Liu YL et al (2022) Risk-reducing bilateral Salpingo-Oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract 18:201\u2013209","journal-title":"JCO Oncol Pract"},{"key":"6892_CR12","first-page":"1","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X et al (2021) Efficacy and safety of PARP inhibitors in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol 11:1\u20139","journal-title":"Front Oncol"},{"key":"6892_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12957-020-01931-7","volume":"18","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World J Surg Oncol 18:517\u2013523","journal-title":"World J Surg Oncol"},{"key":"6892_CR14","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.24200","volume":"115","author":"MJ Hall","year":"2009","unstructured":"Hall MJ et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222\u20132233","journal-title":"Cancer"},{"key":"6892_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","volume":"1","author":"R Janavi\u010dius","year":"2010","unstructured":"Janavi\u010dius R (2010) Founder BRCA1\/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA Journal 1:397\u2013412","journal-title":"EPMA Journal"},{"key":"6892_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","volume":"7","author":"JD Fackenthal","year":"2007","unstructured":"Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937\u2013948","journal-title":"Nat Rev Cancer"},{"key":"6892_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31853","author":"SDJ Pena","year":"2020","unstructured":"Pena SDJ, Santos FR, Tarazona-Santos E (2020) Genetic admixture in Brazil. Am J Med Genet C Semin Med Genet. https:\/\/doi.org\/10.1002\/ajmg.c.31853","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"6892_CR18","doi-asserted-by":"publisher","first-page":"80465","DOI":"10.18632\/oncotarget.12610","volume":"7","author":"GC Fernandes","year":"2016","unstructured":"Fernandes GC et al (2016) Prevalence of BRCA1\/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 7:80465\u201380481","journal-title":"Oncotarget"},{"key":"6892_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-27315-2","volume":"8","author":"EI Palmero","year":"2018","unstructured":"Palmero EI et al (2018) The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep 8:1\u201310","journal-title":"Sci Rep"},{"key":"6892_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JGO.19.00170","volume":"6","author":"MI Achatz","year":"2020","unstructured":"Achatz MI et al (2020) Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil. J Glob Oncol 6:439\u2013452","journal-title":"J Glob Oncol"},{"key":"6892_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB et al (2021) Genetic\/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021. JNCCN J Nat Compr Cancer Netw 19:77\u2013102","journal-title":"JNCCN J Nat Compr Cancer Netw"},{"key":"6892_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17:405\u2013424","journal-title":"Genet Med"},{"key":"6892_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"X Li","year":"2018","unstructured":"Li X et al (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 and BRCA2 mutation. Hum Mutat 39:593\u2013620","journal-title":"Hum Mutat"},{"key":"6892_CR24","first-page":"1","volume":"103","author":"SM Harrison","year":"2020","unstructured":"Harrison SM et al (2020) 2020 Overview of specifications to the ACMG\/AMP variant interpretation guidelines. Curr Protoc Hum Genet 103:1\u201320","journal-title":"Curr Protoc Hum Genet"},{"key":"6892_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.294.15.1925","volume":"294","author":"R Nanda","year":"2005","unstructured":"Nanda R et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women. JAMA 294:1925","journal-title":"JAMA"},{"key":"6892_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/ejhg.2010.203","volume":"19","author":"N Hamel","year":"2011","unstructured":"Hamel N et al (2011) On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19:300\u2013306","journal-title":"Eur J Hum Genet"},{"key":"6892_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck TR et al (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593\u2013620","journal-title":"Hum Mutat"},{"key":"6892_CR28","first-page":"1","volume":"10","author":"ES dos Santos","year":"2018","unstructured":"dos Santos ES et al (2018) Non-coding variants in BRCA1 and BRCA2 genes: potential impact on breast and ovarian cancer predisposition. Cancers (Basel) 10:1\u201321","journal-title":"Cancers (Basel)"},{"key":"6892_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/humu.22159","volume":"33","author":"BL Brewster","year":"2012","unstructured":"Brewster BL et al (2012) Identification of fifteen novel germline variants in the BRCA1 3\u2032UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat 33:1665\u20131675","journal-title":"Hum Mutat"},{"key":"6892_CR30","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S et al (2018) Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol 25:2925\u20132931","journal-title":"Ann Surg Oncol"},{"key":"6892_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2018","unstructured":"Beitsch PD et al (2018) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453\u2013460","journal-title":"J Clin Oncol"},{"key":"6892_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 28:1167\u20131180. https:\/\/doi.org\/10.1007\/s12282-020-01148-2","journal-title":"Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06892-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T02:04:26Z","timestamp":1682733866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6892"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06892-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee from Hospital 9 de Julho (CAAE: 53253821.8.0000.5455), and all patients provided an informed consent for genetic testing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}